Astellas expecting strong Xtandi growth as currency boosts 1Q
This article was originally published in Scrip
Executive Summary
Following its launch in the US last September, Astellas is forecasting rapid growth for Xtandi (enzalutamide) in what is set to be the prostate cancer drug's largest single market. Although sales were a modest at $82m (JPY8.5bn) in the Japanese firm's fiscal first quarter, they are expected to top $400m (JPY40.0bn) for the full year ending next 31 March as promotional efforts gather steam.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.